Extraprise

Srikant M. Datar; Krishna G. Palepu; Sarah S. Khetani

Case | HBS Case Collection | August 2000 (Revised September 2000)

Extraprise

by Srikant M. Datar, Krishna G. Palepu and Sarah S. Khetani

Abstract

In the three years since it was founded, the Boston-based Internet strategy consulting firm, Extraprise, has changed its strategy three times. Jennifer Gabler, the CFO, considers what kinds of control systems she can put in place to ensure the company can continue to achieve operational excellence. With company growth and market changes happening so rapidly, how can the company ensure that it will always be able to turn on a dime? What kind of control would be most effective?

Keywords: Information Management; Management Analysis, Tools, and Techniques; Mathematical Methods; Information Technology; Outcome or Result; Business Growth and Maturation; Growth and Development Strategy; Web Services Industry; Information Technology Industry; Boston;

Format: Print

33 pages

Educators

Citation:

Datar, Srikant M., Krishna G. Palepu, and Sarah S. Khetani. "Extraprise." Harvard Business School Case 101-001, August 2000. (Revised September 2000.)

Tesla’s board of directors proposed an unusual compensation plan for the company’s CEO Elon Musk. The plan payouts were entirely contingent on achieving very ambitious market value, sales, and EBIT targets over the next ten years. If all the targets were achieved, Tesla would be one of the most valuable companies in the world, and Musk would receive the highest compensation of any CEO in U.S. corporate history. If the targets were not achieved, Musk would receive nothing. Proxy advisors (ISS and Glass Lewis) expressed serious reservations about the plan and urged shareholders to vote against it. Should shareholders approve or reject the plan?

We describe how Coronary Artery Bypass Grafting (CABG, or more popularly, “bypass”) operations revolutionized the treatment of coronary disease (that can produce fatal heart attacks and debilitating angina). Specifically we chronicle the 1) development of the foundational procedures and technologies that provided a base for CABG; 2) early CABG operations performed in the 1960s; 3) rapid—and controversial growth—that occurred in the U.S. in the 1970s and; 4) emergence and rapid diffusion of the less invasive angioplasty alternative that slowed the growth of CABG in the last two decades of the 20th century.

The case traces the rise of Enron, covering the company's business innovations, personnel management, and risk management processes. It then examines the company's dramatic fall including the extension of its trading model into questionable new businesses, the financial reporting problems, and governance breakdowns inside and outside the firm. The case offers students an opportunity to explore why Enron failed and to understand the systemic problems in governance that affected its board of directors, the audit committee, the external auditors, and financial analysts.

Faculty & Research

Extraprise

Abstract

Citation:

About the Authors

More from these Authors